cancer treatment

Northwest Biotherapeutics (NWBO) announced the passing of Senior Vice President and General Counsel, Les Goldman. Goldman was a key contributor to NWBO, a biotech firm focused on personalized immune therapies for solid tumor cancers, particularly via its DCVax® platform. NWBO is advancing DCVax®-L for glioblastoma, with UK regulatory review underway. They are also developing DCVax®-Direct for inoperable solid tumors. His responsibilities are being assumed by existing management.

Arcus Biosciences’ shares surged after promising Phase 1/1b data for its casdatifan-cabozantinib combo in clear cell renal cell carcinoma (ccRCC. The ARC-20 study showed a 46% confirmed overall response rate, exceeding historic benchmarks. Arcus plans Phase 3 trials (PEAK-1) and others evaluating the combination in various ccRCC treatment settings. The positive results highlight the potential to change standards of care for patients whose ccRCC has advanced despite prior immunotherapy treatment.